VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Borghaei on Reporting Immunotherapy-Related AEs in Lung Cancer

Hossein Borghaei, DO
Published: Friday, Jan 20, 2017



Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

This is always a difficult discussion because some patients are fearful that if they report side effects from their immunotherapy, that the drug, or any treatment, will be discontinued. However, he explains, patients should understand that this is not necessarily the case. There are other potential agents available or other clinical trials they could possibly enroll on, if the AEs cannot be managed.

It is important to emphasize that if some of the side effects are managed quickly, patients could potentially be challenged to be treated with the immunotherapy again. However, if these toxicities are not reported, they can be associated with very serious side effects, Borghaei says.


Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

This is always a difficult discussion because some patients are fearful that if they report side effects from their immunotherapy, that the drug, or any treatment, will be discontinued. However, he explains, patients should understand that this is not necessarily the case. There are other potential agents available or other clinical trials they could possibly enroll on, if the AEs cannot be managed.

It is important to emphasize that if some of the side effects are managed quickly, patients could potentially be challenged to be treated with the immunotherapy again. However, if these toxicities are not reported, they can be associated with very serious side effects, Borghaei says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Updates in Novel Therapeutic Options for Lung Neuroendocrine TumorsMay 31, 20181.0
Community Practice Connections™: Working Group to Optimize Outcomes in EGFR-mutated Lung Cancers: Evolving Concepts for Nurses to Facilitate and Improve Patient CareJun 30, 20181.5
Publication Bottom Border
Border Publication
x